Hertab (Lapatinib) 250 mg
Hertab (Lapatinib) 250 mg is a targeted oral therapy for HER2-positive advanced breast cancer.
Manufacturer: Hetero Healthcare Limited (India). A globally recognized oncology-focused pharmaceutical company with WHO-GMP certification.
Mechanism of Action:
Lapatinib is a dual tyrosine kinase inhibitor (TKI) that simultaneously blocks both HER1 (EGFR) and HER2 intracellular signaling pathways. Unlike monoclonal antibodies, it works inside the cell, disrupting tumor growth signals at the source.
β Key Advantage: Oral administration and intracellular action make it effective in patients with progression or resistance to trastuzumab-based regimens.
Approved indications:
- ποΈ HER2-positive Advanced/Metastatic Breast Cancer: In combination with capecitabine, for patients who have received prior anthracycline, taxane, and trastuzumab therapy.
- HR+/HER2+ Metastatic Breast Cancer: In combination with letrozole, for postmenopausal women not candidates for chemotherapy.
Standard Dosing:
- With capecitabine: 1,250 mg (5 tablets) once daily, continuously.
- With letrozole: 1,500 mg (6 tablets) once daily, continuously.
β οΈ CRITICAL FOOD INTERACTION:
- π« Take on an empty stomach. Food significantly increases drug absorption, raising the risk of toxicity.
- β° Take at least 1 hour before or 1 hour after a meal, at the same time each day.
- Swallow tablets whole β do not crush, chew, or split.
π‘ If a dose is missed, skip it β do not double the next dose.
- Severe hepatic impairment (dose reduction or discontinuation required).
- Known QTc prolongation or predisposition to arrhythmias.
- Pregnancy and breastfeeding.
- Concurrent use of strong CYP3A4 inhibitors or inducers (e.g., ketoconazole, rifampin) β use with caution.
- Known hypersensitivity to lapatinib or excipients.
Most common adverse effects:
- π Diarrhea: Most frequent. Begin anti-diarrheal therapy at first sign. Dehydration can be severe.
- Acneiform Rash: Typical of EGFR inhibitors. Use moisturizers and sun protection.
- Nausea/Vomiting: Usually mild to moderate and manageable.
- β οΈ Decreased Left Ventricular Ejection Fraction (LVEF): Cardiac monitoring (ECHO/MUGA) required before and during treatment.
- Elevated liver enzymes (ALT/AST): Regular blood chemistry monitoring needed.
- Fatigue, headache, hand-foot syndrome (with capecitabine combination).
What Customers Say
No reviews yet
Your review can be the first!